Lumira Ventures

Lumira Ventures, established in 2007, is a prominent North American venture capital firm specializing in healthcare and life sciences investments. Based in Toronto, with additional offices in Montreal, Vancouver, and Boston, the firm focuses on emerging, mid, and late-stage companies in biotechnology, biopharmaceuticals, medical devices, digital health, and consumer health sectors. Lumira Ventures invests between $5 million to $15 million, providing not only capital but also active board participation, access to funding sources, partners, and market access to maximize the value of its portfolio companies' technology pipelines. With a 30-year history, the firm has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies across Canada and the United States.

Gerry Brunk, MBA

Managing Director

Daniel Hetu

Managing Director

Vasco Larcina

CFO

Alice Luo

Analyst

David Novak

Venture Partner

Suman Rao

Senior Associate

Benjamin Rovinski, Ph.D.

Managing Director

Nikhil Thatte

Principal

Peter van der Velden, MBA, M.Sc.

Managing General Partner

Baye Galligan

Director of Research

Past deals in Minnesota

HistoSonics

Series D in 2024
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

HistoSonics

Convertible Note in 2022
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

HistoSonics

Series C in 2020
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

HistoSonics

Series C in 2019
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.